New polio vaccine trial aims to boost eradication efforts
NCT ID NCT05644184
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral polio vaccine (nOPV1) in over 2,200 healthy young children, infants, and newborns in Bangladesh. Researchers will compare it to the current Sabin vaccine to see if it is safe and triggers a strong immune response. The goal is to find a more stable vaccine that could help finally wipe out polio.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Novel live attenuated type 1 oral poliomyelitis vaccine (nOPV1)
- What this could lead to
- If successful, this could provide a safer, more stable polio vaccine to help eradicate polio worldwide.
- What could go wrong
- This is an early phase 2 trial, so safety and effectiveness are not yet proven. The vaccine may cause side effects or not generate strong immunity in all age groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLIOMYELITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
RECRUITINGDhaka, 1212, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Virus-Like particle vaccine outsmart polio?
- Can breathing power boost balance and Well-Being in paralympic athletes?
- New polio vaccine trial aims to protect the youngest
- Polio vaccine showdown: which sequence protects best?
- Virtual walking lifts spirits for those who cannot walk
- AI vs. experts: can a computer judge speech as well as a human?